ABC | Volume 114, Nº4, Abril 2020

Artigo Original Scherr et al. Interleucina 18, proteína precursora do trombo DAC Arq Bras Cardiol. 2020; 114(4):692-698 Conclusões As concentrações médias de IL-18 e TpP encontram-se elevadas na fase aguda da doença arterial coronariana, sugerindo correlação desse biomarcador com a agudização e instabilidade da síndrome coronariana aguda. As concentrações médias de IL-8 e TpP foram menores na fase crônica da doença coronariana e nos pacientes do grupo-controle; entretanto, neste estudo observou-se que o grupo crônico e o grupo-controle apresentaram médias estatisticamente equivalentes. Os resultados não sofreram influência das diferenças de sexo e etnia dos grupos. Contribuição dos autores Concepção e desenho da pesquisa e revisão crítica do manuscrito quanto ao conteúdo intelectual importante: Scherr C, Albuquerque DC; Obtenção de dados: Scherr C, Ataide K, Ludmila T, Blanco F, Mangia CM; Análise e interpretação dos dados e redação do manuscrito: Scherr C, Albuquerque DC, Ataide K; Análise estatística: Scherr C, Albuquerque DC, Pozzan R; Obtenção de financiamento: Scherr C, Albuquerque DC, Ludmila T. Potencial conflito de interesses Declaro não haver conflito de interesses pertinentes. Fontes de financiamento O presente estudo foi financiado pela Fundação Pró Coração. Vinculação acadêmica Este artigo é parte de tese de Pós-Doutorado de Carlos Scherr pela Universidade do Estado do Rio de Janeiro. 1. GoAS,MozaffarianD,RogerVL,BenjaminEJ,BerryJD,BordenWB,etal.Heart disease and stroke statistics – 2013 update: a report from the American Heart Association.Circulation.2013;127(1):e6-245. 2. Bouras G, Deftereos S. Editorial (hot topic: cardiovascular disease biomarkers: fromtraditiontomodernity).CurrTopMedChem.2013;13(2):79-81. 3. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations.Circulation.2006;113(19):2335-62. 4. HackamDG,AnandSS.Emergingriskfactorsforatheroscleroticvasculardisease: acriticalreviewoftheevidence. JAMA.2003;290(7):932-40. 5. ShahPK.Biomarkersofplaque instability.CurrCardiolRep.2014;16(12):547. 6. Nicolletti A, Caligiuri G, Hansson GK. Immunomodulation of atherosclerosis: mythandreality. J InternMed.2000;247(3):397-405. 7. KunschC,MedfordRM.Oxidativestressasaregulatorofgeneexpression inthe vasculature.CircRes.1999;85(8):753-66. 8. Abela OG, Ahsan CH, Alreefi F, Salehi N, Baig I, Janoudi A, et al. Erratum to: plaqueruptureandthrombosis:thevalueoftheatheroscleroticrabbitmodel in definingthemechanism.CurrAtherosclerRep.2016;18(8):52. 9. Mega JL, Morrow DA, Lemos JA, Mohanavelu S, Cannon CP, Sabatine MS. Thrombus precursor protein and clinical outcomes in patients with acute coronarysyndromes. JAmCollCardiol.2008;51(25):2422-9. 10. Hartford M, Wiklund O, Hultén LM, Persson A, Karlsson T, Herlitz J, et al. Interleukin-18 as a predictor of future events in patients with acute coronary syndromes.ArteriosclerThrombVascBiol.2010;30(10):2039-46. 11. Balta S, Demirkol S, Kucuk U, Unlu M, Ay SA, Arslan Z, et al. Inflammatory markers may predict long-term cardiovascular mortality in patients with acute coronarysyndrome.Cardiology.2013;125(2):88-9. 12. OpstadTB, ArnesenH, PettersenAÅ, SeljeflotI.Combinedelevatedlevelsofthe proinflammatorycytokinesIL-18andIL-12areassociatedwithclinicalevents in patientswithcoronaryart erydisease:anobservationalstudy.MetabSyndrRelat Disord.2016;14(5):242-8. 13. MallatZ,HenryP,FressonnetR,AlouaniS,ScoazecA,BeaufilsP,etal.Increased plasma concentrations of interleukin-18 in acute coronary syndromes. Heart. 2002;88(5):467-9. 14. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 2002;106(1):24-30. 15. Opstad TB, Pettersen AA, Arnesen H, Seljeflot I. Circulating levels of IL- 18 are significantly influenced by the IL-18 +183 A/G polymorphism in coronary artery disease patients with diabetes type 2 and the metabolic syndrome: an observational study. Cardiovasc Diabetol. 2011 Dec 5;10:110. 16. Suchanek H, My ś liwska J, Siebert J, Wieckiewicz J, Hak Ł, Szyndler K, et al. High serum interleukin-18 concentrations in patients with coronary artery disease and type 2 diabetes mellitus. Eur Cytokine Netw. 2005;16(3):177-85. 17. Jin DY , Liu CL, Tang JN, Zhu ZZ, Xuan XX, Zhu XD, et al. Interleukin-18, matrix metalloproteinase-22 and -29 are independent risk factors of human coronary heart disease. 2017;18(8):685-95. 18. Li Q, Kuang Y , Qiu J , Zhang X, Ruan Y, Li Z. The correlation between plasma tissue factor and interleukin 18 and their significance in patients with acute coronary syndrome. Cardiovasc Toxicol. 2015;15(3):276-82. 19. Goetze JP. Markers of activated coagulation in acute coronary syndromes. J Am Coll Cardiol. 2008;51(25):2430-1. 20. Mega JL, MorrowDA, Lemos JA, Mohanavelu S, Cannon CP, Sabatine MS. Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes. J Am Coll Cardiol. 2008;51(25):2422-9. 21. Laurino JP, Pelletier TE, Eadry R, Kounavis A. Thrombus precursor protein and the measurement of thrombosis in patients with acute chest pain syndrome. Ann Clin Lab Sci. 1997;27(5):338-45. 22. Empana JP, Canoui-Poitrine F, Luc G, Juhan-Vague I, Morange P, Arveiler D, et al. Contribution of novel biomarkers to incident stable angina and acute coronary syndrome: the PRIME Study. Eur Heart J. 2008;29(16):1966-74. 23. Sambola A, Osende J, Hathcock J, Degen M, Nemerson Y, Fuster V, et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation. 2003;107(7):973-7. 24. Lee AJ. The role of rheological and haemostatic factors in hypertension. J Hum Hypertens. 1997;11(12):767-76. Referências Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 698